- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00830466
A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.
The researchers want to collect data on safety and efficacy of combined pulsed dye laser and rapamycin to improve fading/blanching of port wine stain birthmarks as compared to pulsed dye laser alone, which is the current standard of care.
This single center pilot and feasibility study will have a target enrollment of 40 port wine stain subjects at the Beckman Laser Institute and Medical Clinic, University of California, Irvine.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will offer two different approaches to the treatment of port wine stain birthmarks.
Study Group Number 1: Port wine stain treated by the pulsed dye laser alone, which is the current standard of care: 20 subjects.
Study Group Number 2: Port wine stain treated by combined pulsed dye laser and rapamycin: 20 subjects.
The researchers want to collect data on safety and efficacy of combined pulsed dye laser and rapamycin to improve fading/blanching of port wine stain birthmarks as compared to pulsed dye laser alone, which is the current standard of care. Twenty subjects will have their entire port wine stain birthmark treated by pulsed dye laser alone. Twenty subjects will have their entire port wine stain birthmark treated by combined pulsed dye laser and rapamycin, which is a drug that prevents the formation of blood vessels in the skin. Safety will be evaluated by searching for any local effects such as injury to the skin or systemic effects such as abnormal blood and/or urine studies. Efficacy will be determined by objectively measuring and comparing the port wine stain fading/blanching responses for the two study groups.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Irvine, California, United States, 92612
- Beckman Laser Institute and Medical Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Port wine stain suitable for comparison testing.
- Age > 13 years of age or older; minor will be accompanied in the room by parents or guardians during laser treatment.
- Apparent good health as documented by medical history.
- Ability to understand and carry out subject instructions.
- Women of childbearing potential must have a negative urinary pregnancy test prior to being started on rapamycin.
- Women of child bearing potential must agree to use a medically acceptable method of contraception throughout the study and for 3 months following discontinuation of rapamycin.
Exclusion Criteria:
- Inability to understand and carry out instructions.
- Pregnancy.
- Abnormal blood or urine tests
- History of cancer.
- History of high cholesterol, lipids or liver disease.
- Allergy to macrolide drugs (e.g., erythromycin).
- Any therapy within the previous two months to the proposed port wine stain treatment sites.
- Current participation in any other investigational drug evaluation.
- Concurrent use of known photosensitizing drugs.
- Concurrent use of immunosuppressive drugs or steroids.
- Concurrent use of any of the following medications: antifungals, antiepileptics, protease inhibitors, cimetidine, cisapride, clarithromycin, dannzol, diltiazem, erythromycin, metoclopramide, rifabutin, rifampin, rifapetine, troleandomycin, or verapamil.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Laser and rapamycin versus laser alone
|
Laser and rapamycin versus laser alone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improved port wine stain fading/blanching after laser treatment
Time Frame: 24 weeks
|
Efficacy will be determined by objectively measuring and comparing the port wine stain fading/blanching responses for subjects treated with combined pulsed dye laser and rapamycin versus pulsed dye laser alone
|
24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: J. Stuart Nelson, M.D.,Ph.D., Beckman Laser Institute and Medical Clinic, University of California Irvine
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Congenital Abnormalities
- Skin Abnormalities
- Hemangioma
- Neoplasms, Vascular Tissue
- Hemangioma, Capillary
- Port-Wine Stain
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- 20086383
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Port Wine Stain
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...CompletedPort-wine StainChina
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompletedPort-wine StainUnited States
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompletedPORT WINE STAINUnited States
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...Completed
-
Centre Hospitalier Universitaire de NiceCompletedPort-wine StainsFrance
-
University of Lausanne HospitalsUnknownPort-wine Stains (PWS)
-
Henry VasconezGraceway Pharmaceuticals, LLCTerminated
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompletedPort Wine StainsUnited States
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...Not yet recruitingPort-Wine Stain | Nevus Flammeus | Port-wine Birthmark
Clinical Trials on Laser and rapamycin versus laser alone
-
Francisco CarmonaCompletedEndometriosis | Laparoscopy | MicroparticleSpain
-
Vanderbilt UniversityCompleted
-
Kasr El Aini HospitalEyecare CenterCompleted
-
Xuanwu Hospital, BeijingRecruitingCritical Limb Ischemia | Infrapopliteal LesionsChina
-
Mansoura UniversityUnknown
-
Mansoura UniversityUnknownVideo Assisted Anal Fistula TreatmentEgypt
-
State University of Minas GeraisFundação de Amparo à Pesquisa do estado de Minas GeraisActive, not recruiting
-
Assiut UniversityActive, not recruitingCervical Spinal Cord InjuryEgypt
-
University of Sao Paulo General HospitalCompletedSubacromial Impingement Syndrome
-
Taipei Medical University WanFang HospitalTerminated